Projects per year
Organization profile
Organisation profile
This doctoral research program was established in collaboration with Academia Sinica to cultivate interdisciplinary research that focuses on tumor-related medicine. Academia Sinica is Taiwan’s leading research institute and has outstanding scientific researchers and cutting-edge equipment for advanced research. TMU also works in collaboration with its three affiliated hospitals and has access to their clinical resources.
Through these relationships, the Cancer Biology and Drug Discovery program offers students a great opportunity to build a career with excellent research support. We enroll top students from around the world, and provide a strong curriculum of interdisciplinary training as well as a learning environment where students work with many research specialists.
From basic research to translational medicine, we develop cutting-edge therapeutic strategies for cancer prevention and treatment. We work hard for cancer patients, seeking to extend their lives and improve their quality of life.
Fingerprint Dive into the research topics where Ph.D. Program for Cancer Molecular Biology and Drug Discovery is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.
Neoplasms
Medicine & Life Sciences
Colorectal Neoplasms
Medicine & Life Sciences
Prostatic Neoplasms
Medicine & Life Sciences
Cells
Chemical Compounds
MicroRNAs
Medicine & Life Sciences
Thyroid Hormones
Medicine & Life Sciences
Apoptosis
Medicine & Life Sciences
Tumors
Chemical Compounds
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Profiles
Hsin-Yi Chen
- Ph.D. Program for Cancer Molecular Biology and Drug Discovery
- TMU Research Center of Cancer Translational Medicine
- Master Program in Graduate Institute of Cancer Biology and Drug Discovery
Person: Researcher
Projects 2012 2020
利用人工智能與機器學習模式開發新型多靶點抗癌藥物的新發展策略
8/1/19 → 7/1/20
Project: A - Government Institution › b - Ministry of Science and Technology
針對PD-L1 表現機制所發展出之口腔癌治療策略(1/3)
8/1/19 → 7/1/20
Project: A - Government Institution › b - Ministry of Science and Technology
Research Output 1996 2019
5
Citations
(Scopus)
1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase
Lai, M. J., Ojha, R., Lin, M. H., Liu, Y. M., Lee, H. Y., Lin, T. E., Hsu, K. C., Chang, C. Y., Chen, M. C., Nepali, K., Chang, J. Y. & Liou, J. P., Jan 15 2019, In : European Journal of Medicinal Chemistry. 162, p. 612-630 19 p.Research output: Contribution to journal › Article
Benzamides
Histone Deacetylases
Tubulin
Heterografts
Inhibitory Concentration 50
1
Citation
(Scopus)
Action of Reverse T3 on Cancer Cells
Lin, H. Y., Tang, H. Y., Leinung, M., Mousa, S. A., Hercbergs, A. & Davis, P. J., Jan 1 2019, In : Endocrine Research.Research output: Contribution to journal › Article
Integrins
Thyronines
Thyroid Hormone Receptors
Neoplasms
Glioblastoma
Alternative splicing in human cancer cells is modulated by the amiloride derivative 3,5-diamino-6-chloro-N-(N-(2,6-dichlorobenzoyl)carbamimidoyl)pyrazine-2-carboxide
Lee, C. C., Chang, W. H., Chang, Y. S., Yang, J. M., Chang, C. S., Hsu, K. C., Chen, Y. T., Liu, T. Y., Chen, Y. C., Lin, S. Y., Wu, Y. C. & Chang, J. G., Jan 1 2019, In : Molecular Oncology.Research output: Contribution to journal › Article
Open Access
Pyrazines
Amiloride
Alternative Splicing
Neoplasms
RNA Sequence Analysis